0
Research Letters |

Topical Aprepitant in Clinical and Experimental Pruritus

Joanna Wallengren, MD, PhD
Arch Dermatol. 2012;148(8):957-959. doi:10.1001/archdermatol.2012.1018.
Text Size: A A A
Published online

Extract

Peroral aprepitant is a nonpeptide inhibitor of tachykinin receptor NK1 approved for use as an antiemetic drug for chemotherapy-induced nausea. Duval and Dubertret1 first reported that peroral aprepitant effectively reduced pruritus in 3 patients with Sézary syndrome. Similar results were obtained later for 6 of 7 patients with erythrodermic cutaneous T-cell lymphoma.2 Ständer et al3 reported an open-label study of 20 patients with chronic pruritus treated for a week with peroral aprepitant. It has been suggested that the effects of aprepitant are related to its preventing of mast-cell activation in the skin.4 The aim of the present study was to test this hypothesis with topical aprepitant.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Grahic Jump Location

Figure. Individual ratings of pruritus on the aprepitant- vs vehicle-treated sides prior to (A), 30 minutes after (B), and 2 hours after (C) application. VAS indicates visual analog scale score.

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
The use of aprepitant in brachioradial pruritus.
JAMA Dermatol 2013;;149(5):627-8.
[Aprepitant and pruritus--comment].
Klin Onkol 2012;;25(6):491-2.
Jobs